TrialBioMed research international2023

Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma.

Yamirka Sánchez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.